Generic Name and Formulations:
Ciprofloxacin (as HCl) 0.3%; oph. soln; contains benzalkonium chloride.
Alcon Laboratories, Inc.
Indications for CILOXAN:
Susceptible infections of conjunctiva and cornea.
Adults and Children:
Conjunctivitis: 1–2 drops in conjunctival sac(s) every 2 hours while awake for 2 days, then 1–2 drops every 4 hours while awake for next 5 days. Corneal ulcers: 2 drops every 15 minutes for 1st 6 hours, then 2 drops every 30 minutes for rest of 1st day; 2nd day: 2 drops every 1 hour; 3rd–14th days: 2 drops every 4 hours. May treat for 14 days or until corneal re-epithelialization occurs.
CNS or convulsive disorders. Discontinue if rash occurs. Pregnancy (Cat.C). Nursing mothers.
May increase theophylline levels. May potentiate oral anticoagulants. May increase renal toxicity with cyclosporine.
Soln: Burning, crystalline precipitates, lid margin crusting, scales, foreign body sensation, pruritus, conjunctival hyperemia, bad taste. Oint: ocular discomfort, blurred vision; may delay corneal healing. Both: superinfection.
Clinical Pain Advisor Articles
- Chronic Neuropathic Pain Updated Classification by IASP for ICD-11
- Buprenorphine-Naloxone Found to Be More Cost-Effective Than Extended-Release Naltrexone
- Ultrasound-Guided C2 Coblation May Be Effective for Cervicogenic Headache
- Meta-Analysis of Opioid Treatment for Chronic Noncancer Pain
- Opioids Found to Increase Risk for Community-Acquired Pneumonia, Particularly in HIV
- Reviewing the Use of Buprenorphine in Perioperative Pain Management
- Early Physical Therapy for Musculoskeletal Pain May Reduce Opioid Use
- External Trigeminal Nerve Stimulation May Alleviate Migraine Pain
- IASP Updates Diagnosis Criteria for Chronic Primary Pain for ICD-11
- Galcanezumab Provides Persistent Preventive Effects in Episodic, Chronic Migraine
- Comparable Analgesia With Low-Dose IV Ketamine, Morphine for Acute Pain
- Benzodiazepines, if Prescribed, May Not Affect Methadone Treatment Retention
- When Opioid Prescribing Guidelines Become Rules
- IV Fluid Confers No Significant Treatment Effect on Migraine Pain
- American Headache Society Releases Position Statement on Novel Preventive and Acute Migraine Treatments